Grant: Operating Grant
McGill University
$349,137.00
Modifying Gene Expression with Synthetic Nucleic Acid Therapeutics
FY 2011-12
Summary
The discovery of RNA interference has set the stage for novel drug discovery programs based on the notion that short pieces of DNA or RNA can be made into drugs. My laboratory at McGill University is interested in generating synthetically modified DNA and RNA structures that are able to "switch off" disease-causing genes, including those related to cancers, inflammation, etc. Interestingly, it turns out that these modified versions of DNA have increased stability to cellular processes that would otherwise degrade them before they could perform their desired functions. Essentially, these molecules are designed to perform a singular function in diseased cells: intercept the messenger RNAs of a disease-related gene, and "switch off" that gene. More specifically, we intend to design and optimize modified nucleic acids which will allow us to slow down the rate at which malignant brain tumors can spread, potentially laying the foundation for development of attractive drug candidates for cancer treatment. Understanding the processes through which our modified compounds function to intercept the messenger RNA is also an important research endeavor within our group. In collaboration with biochemists and cellular biologists, we will study the enzymes involved in RNA recognition, because a thorough understanding of this process will aid in the design of more potent nucleic acid derivatives. These proposed studies expose my graduate and postdoctoral students to a wide range of nucleic acid chemistry and biology research, and to strategies used for identifying candidate molecules and developing them into useful therapeutic drugs.
Department
Program
Operating Grant
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
239159
Name
Damha Masad J
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Pharmaceutical Sciences
Projecttitle
Modifying Gene Expression with Synthetic Nucleic Acid Therapeutics
Programtype2
Operating Grants
Orgnameinp2
McGill University
Cihramount2
$349,137
Cihrequipment2
$0
Programname2
Operating Grant
Keyworddelim
Anticancer; Control Of Gene Expression; Nucleoside Analogues; Oligonucleotide Therapeutics; Rnai And Antisense; Structural And Mechanistic Studies Of Nucleic Acids
Abstract
The discovery of RNA interference has set the stage for novel drug discovery programs based on the notion that short pieces of DNA or RNA can be made into drugs. My laboratory at McGill University is interested in generating synthetically modified DNA and RNA structures that are able to "switch off" disease-causing genes, including those related to cancers, inflammation, etc. Interestingly, it turns out that these modified versions of DNA have increased stability to cellular processes that would otherwise degrade them before they could perform their desired functions. Essentially, these molecules are designed to perform a singular function in diseased cells: intercept the messenger RNAs of a disease-related gene, and "switch off" that gene. More specifically, we intend to design and optimize modified nucleic acids which will allow us to slow down the rate at which malignant brain tumors can spread, potentially laying the foundation for development of attractive drug candidates for cancer treatment. Understanding the processes through which our modified compounds function to intercept the messenger RNA is also an important research endeavor within our group. In collaboration with biochemists and cellular biologists, we will study the enzymes involved in RNA recognition, because a thorough understanding of this process will aid in the design of more potent nucleic acid derivatives. These proposed studies expose my graduate and postdoctoral students to a wide range of nucleic acid chemistry and biology research, and to strategies used for identifying candidate molecules and developing them into useful therapeutic drugs.
Competitiondate
201109
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Damha, Masad J
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $349,137~ $0~